Cargando…
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
The goal of this phase I study was to develop a novel schedule using oral etoposide and infusional topotecan as a continually alternating schedule with potentially optimal reciprocal induction of the nontarget topoisomerase. The initial etoposide dose was 15 mg m(−2) b.i.d. days (D)1–5 weeks 1,3,5,7...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361482/ https://www.ncbi.nlm.nih.gov/pubmed/15986034 http://dx.doi.org/10.1038/sj.bjc.6602671 |